|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM204092345 |
| 003 |
DE-627 |
| 005 |
20231223231356.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2011 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.11.002
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0680.xml
|
| 035 |
|
|
|a (DE-627)NLM204092345
|
| 035 |
|
|
|a (NLM)21130040
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Huang, Mei-Chuan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 21.03.2011
|
| 500 |
|
|
|a Date Revised 20.10.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Lenalidomide, an analog of thalidomide, modified responses of stimulated T cells from healthy young (ages 21-40 years) and old (≥ age 65 years) subjects. At 0.03 μM to 1 μM, lenalidomide enhanced generation of IL-2 and IFN-γ by T cell receptor-stimulated T cells of young subjects up to respective maximum increases of 17-fold and three-fold, but at 0.3 μM and 1 μM suppressed IL-17 generation. The same concentrations of lenalidomide enhanced IL-2 and IFN-γ generation by stimulated T cells of old subjects more, with greater respective maximal increases of up to 120-fold and six-fold, without suppressing IL-17 generation. Lenalidomide enhanced proliferation and suppressed apoptosis of stimulated T cells from old subjects, by IL-2-dependent mechanisms, and restored diminished T cell chemotactic responses to CCL21 and sphingosine 1-phosphate. The reversal of T cell abnormalities of immunosenescence by low concentrations of lenalidomide suggest a potential for improvement of immunity in the elderly
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Intramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a CCL21 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Chemokine CCL21
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a bcl-X Protein
|2 NLM
|
| 650 |
|
7 |
|a Thalidomide
|2 NLM
|
| 650 |
|
7 |
|a 4Z8R6ORS6L
|2 NLM
|
| 650 |
|
7 |
|a Lenalidomide
|2 NLM
|
| 650 |
|
7 |
|a F0P408N6V4
|2 NLM
|
| 700 |
1 |
|
|a Greig, Nigel H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Weiming
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tweedie, David
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schwartz, Janice B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Longo, Dan L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ferrucci, Luigi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ershler, William B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Goetzl, Edward J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 138(2011), 2 vom: 14. Feb., Seite 201-11
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:138
|g year:2011
|g number:2
|g day:14
|g month:02
|g pages:201-11
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.11.002
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 138
|j 2011
|e 2
|b 14
|c 02
|h 201-11
|